Janssen
Johnson & Johnson Innovative Medicine is dedicated to developing science-based innovations to change and save lives. Inspired by patients and the legacy of Dr. Paul Janssen, the company focuses on complex diseases, pioneering treatments, and unlocking potential medicines of tomorrow. It spans multiple therapeutic areas including Oncology, Immunology, Neuroscience, Cardiopulmonary, and Specialty Ophthalmology, and collaborates globally to bring health breakthroughs to market faster.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Products
Portfolio of prescription medicines and vaccines
A portfolio of investigational and approved therapeutic and preventive products spanning oncology, immunology, neuroscience, cardiopulmonary diseases, specialty ophthalmology and communicable diseases.
Portfolio of prescription medicines and vaccines
A portfolio of investigational and approved therapeutic and preventive products spanning oncology, immunology, neuroscience, cardiopulmonary diseases, specialty ophthalmology and communicable diseases.
Services
Structured programs to form academic, industry and non-profit partnerships for discovery, clinical development and access initiatives.
Grant funding and engagement with patient organizations to support education, research and improved clinical trial participation.
Identification, valuation and progression of external investment and partnership opportunities to advance innovation priorities.
Regulatory engagement, submissions and market access strategy to support approvals, labeling and reimbursement across regions.
Identification and assessment of external scientific and technological opportunities to inform prevention and early-development portfolios.
Structured programs to form academic, industry and non-profit partnerships for discovery, clinical development and access initiatives.
Grant funding and engagement with patient organizations to support education, research and improved clinical trial participation.
Identification, valuation and progression of external investment and partnership opportunities to advance innovation priorities.
Regulatory engagement, submissions and market access strategy to support approvals, labeling and reimbursement across regions.
Identification and assessment of external scientific and technological opportunities to inform prevention and early-development portfolios.
Expertise Areas
- Clinical trial management
- Data science and AI for drug development
- Biomarker discovery and translational research
- Microbiome therapeutics
Key Technologies
- AI-driven analytics
- Digital health platforms
- Microbiome modulation approaches
- Biomarker assays and validation
News & Updates
Approval provides a new treatment option for some of the youngest people living with HIV-1 in the European Union.
FDA approval for pediatric use of rilpivirine in children weighing 14 to less than 25 kg.
Partnership to develop innovative vaccine solutions.
The trial was discontinued as part of ongoing research efforts.
The WHO updated emergency use listing for the Johnson & Johnson COVID-19 vaccine.
Exploring how targeted, personalized care is transforming treatment outcomes.
Approval provides a new treatment option for some of the youngest people living with HIV-1 in the European Union.
FDA approval for pediatric use of rilpivirine in children weighing 14 to less than 25 kg.
Partnership to develop innovative vaccine solutions.
The trial was discontinued as part of ongoing research efforts.
The WHO updated emergency use listing for the Johnson & Johnson COVID-19 vaccine.
Exploring how targeted, personalized care is transforming treatment outcomes.